# EDGAR Filing Document

**Accession Number:** 0000883975
**File Stem:** 0001641172-25-020076
**Filing Date:** 2025-7
**Character Count:** 5791
**Document Hash:** acbfa29a668815389835b7a99dc5d48f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-020076.hdr.sgml**: 20250717

**ACCESSION NUMBER**: 0001641172-25-020076

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250714

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250717

**DATE AS OF CHANGE**: 20250717

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Microbot Medical Inc.
- **CENTRAL INDEX KEY:** 0000883975
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 943078125
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19871
- **FILM NUMBER:** 251131331

**BUSINESS ADDRESS:**
- **STREET 1:** 25 RECREATION PARK DR SUITE 108
- **CITY:** HINGHAM
- **STATE:** MA
- **ZIP:** 02043
- **BUSINESS PHONE:** 908-938-5561

**MAIL ADDRESS:**
- **STREET 1:** 25 RECREATION PARK DR SUITE 108
- **CITY:** HINGHAM
- **STATE:** MA
- **ZIP:** 02043

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STEMCELLS INC
- **DATE OF NAME CHANGE:** 20000524

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTOTHERAPEUTICS INC/DE
- **DATE OF NAME CHANGE:** 19930328

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 14, 2025**

**MICROBOT MEDICAL INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-19871** | **94-3078125** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission** <br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| |
|:---|
| **175 Derby St., Bld. 27**<br> **Hingham, MA 02043** |
| **(Address of Principal Executive Offices) (Zip Code)** |

---

**Registrant's telephone number, including area code: (781) 875-3605**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.01 par value | MBOT | NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 3.02. Unregistered Sales of Equity Securities.**

Since June 18, 2025, Microbot Medical Inc. (the "Company") issued an aggregate of 1,808,336 shares of its common stock, par value $0.01 per share (the "Shares"), upon the exercise of an aggregate of 1,025,000 outstanding Series G preferred investment options (the "Series G Options") and 783,336 Series F preferred investment options (the "Series F Options" and, collectively with the Series G Options, the "Options"), by the holders of the Options. The exercise price per share of the Series G Options was $1.75, generating gross proceeds to the Company, before deducting placement agent fees and expenses, of approximately $1.8 million. The exercise price per share of the Series F Options was $1.50, generating gross proceeds to the Company, before deducting placement agent fees and expenses, of approximately $1.175 million.

The Shares were issued pursuant to the exemption provided in Section 4(a)(2) under the Securities Act of 1933, as amended, as transactions by an issuer not involving any public offering.

Each of the Shares underlying the Series G Options were registered by the Company for resale on a Registration Statement on Form S-3 (Registration No.: 333-284688) on behalf of the holders of the Series G Options. Each of the Shares underlying the Series F Options were registered by the Company for resale on a Registration Statement on Form S-3 (Registration No.: 333-280113) on behalf of the holders of the Series F Options.

**Item 9.01** **Financial Statements and Exhibits**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MICROBOT MEDICAL INC.** | **MICROBOT MEDICAL INC.** |
|  | By: | */s/ Harel Gadot* |
|  | Name: | Harel Gadot |
|  | Title: | Chief Executive Officer, President and Chairman |
| Date: July 17, 2025 |  |  |

---